ConductScience.org, home

Paper20535784

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.

Caporali R and 6 others. Arthritis Care Res (Hoboken), 2010. Cited by 96 papers, by iCite.

Cite this record

ConductScience Library. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Papers, record 20535784. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20535784

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
PubMed
Journal
Arthritis Care Res (Hoboken)
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Multicenter Study
PubMed
Citations, by iCite
96
iCite
Relative citation ratio, by iCite
3.24
iCite
Revised in PubMed
2022-03-18
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Caporali RR
2Bobbio-Pallavicini FF
3Atzeni FF
4Sakellariou GG
5Caprioli MM
6Montecucco CC
7Sarzi-Puttini PP

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Carrier StateMajor topic
Hepatitis B Surface AntigensMajor topic
Hepatitis B virusMajor topic
Rheumatic DiseasesMajor topic
Tumor Necrosis Factor-alphaMajor topic
Adult
Aged
Cohort Studies
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prospective Studies

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04356404Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst PatientsBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.

PMIDTitleJournalYearIn PapersSource
38734770Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study.Arch Dermatol Res2024https://conductscience.org/library/papers/38734770PubMed
37751983Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.BMJ Case Rep2023https://conductscience.org/library/papers/37751983PubMed
36840482Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.Immun Inflamm Dis2023https://conductscience.org/library/papers/36840482PubMed
36744250Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review.Front Pharmacol2023https://conductscience.org/library/papers/36744250PubMed
36323488Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.RMD Open2022https://conductscience.org/library/papers/36323488PubMed
32897226Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.Turk J Gastroenterol2020https://conductscience.org/library/papers/32897226PubMed
32206094Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.Ther Adv Musculoskelet Dis2020https://conductscience.org/library/papers/32206094PubMed
32098857Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.RMD Open2020https://conductscience.org/library/papers/32098857PubMed
29991894Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.Ann Gastroenterol2018https://conductscience.org/library/papers/29991894PubMed
29968197Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.Clin Drug Investig2018https://conductscience.org/library/papers/29968197PubMed
29694398Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.PLoS One2018https://conductscience.org/library/papers/29694398PubMed
29164002Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series.Eur J Rheumatol2017https://conductscience.org/library/papers/29164002PubMed
29089055Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study.Arthritis Res Ther2017https://conductscience.org/library/papers/29089055PubMed
28834412Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.Arthritis Care Res (Hoboken)2018https://conductscience.org/library/papers/28834412PubMed
28090316The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde.Clin Transl Immunology2016https://conductscience.org/library/papers/28090316PubMed
27605880Management of psoriasis patients with hepatitis B or hepatitis C virus infection.World J Gastroenterol2016https://conductscience.org/library/papers/27605880PubMed
26573663Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.Rheumatol Int2016https://conductscience.org/library/papers/26573663PubMed
26420955Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.World J Gastroenterol2015https://conductscience.org/library/papers/26420955PubMed
26001631Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.Arthritis Res Ther2015https://conductscience.org/library/papers/26001631PubMed
25848463Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.World J Hepatol2015https://conductscience.org/library/papers/25848463PubMed

See all 32 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20535784

GET https://conductscience.org/api/papers/v1/20535784/cited_by?page=2